Anil K. Verma

Dr. Anil K. Verma

Medicine, McMaster University, Hamilton, Ontario, Canada
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2011 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
GMGovind Makharia
Govind Makharia
Anil K. VermaAnil K. Verma
Anil K. Verma
RARitvik Amarchand
Ritvik Amarchand
SBShinjini Bhatnagar
Shinjini Bhatnagar
PDPrasenjit Das
Prasenjit Das
KAKrishnan Anand
Krishnan Anand

1 January 2016 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
BRBalakrishnan Ramakrishna
Balakrishnan Ramakrishna
GMGovind K Makharia
Govind K Makharia
KCKamal Chetri
Kamal Chetri
SDSangitanjan Dutta
Sangitanjan Dutta
PMPrashant Mathur
Prashant Mathur
Anil K. VermaAnil K. Verma
Anil K. Verma
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

31 January 2011 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
GMGovind Makharia
Govind Makharia
Anil K. VermaAnil K. Verma
Anil K. Verma
RARitvik Amarchand
Ritvik Amarchand
AGAnil Goswami
Anil Goswami
PSPrashant Singh
Prashant Singh
AKAnand Krishnan
Anand Krishnan
Makharia GK, et al. J Neurogastroenterol Motil. 2011 Jan;17(1):82-87. http://dx.doi.org/10.5056/jnm.2011.17.1.82

8 February 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
RBRahul Bodkhe
Rahul Bodkhe
SSSudarshan A. Shetty
Sudarshan A. Shetty
DDDhiraj Dhotre
Dhiraj Dhotre
Anil K. VermaAnil K. Verma
Anil K. Verma
KBKhushbo Bhatia
Khushbo Bhatia
GMGovind Makharia
Govind Makharia
Recent studies on celiac disease (CeD) have reported alterations in the gut microbiome. Whether this alteration in the microbial community is the cause or effect of the disease is not well understood, especially in adult onset of disease. The first-degree relatives (FDRs) of CeD patients may provide an opportunity to study gut microbiome in pre-disease state as FDRs are genetically susceptible to CeD. By using 16S rRNA gene sequencing, we observed that ecosystem level diversity measures were not significantly different between the disease condition (CeD), pre-disease (FDR) and control subjects. However, differences were observed at the level of amplicon sequence variant (ASV), suggesting alterations in specific ASVs between pre-disease and diseased condition. Duodenal biopsies showed higher differences in ASVs compared to fecal samples indicating larger disruption of the microbiota at the disease site. The duodenal microbiota of FDR was characterized by significant abundance of ASVs belonging to Parvimonas, Granulicatella, Gemella, Bifidobacterium, Anaerostipes and Actinomyces genera. The duodenal microbiota of CeD was characterized by higher abundance of ASVs from genera Megasphaera and Helicobacter compared to the FDR microbiota. The CeD and FDR fecal microbiota had reduced abundance of ASVs classified as Akkermansia and Dorea when compared to control group microbiota. In addition, predicted functional metagenome showed reduced ability of gluten degradation by CeD fecal microbiota in comparison to FDRs and controls. The findings of the present study demonstrate differences in ASVs and predicts reduced ability of CeD fecal microbiota to degrade gluten compared to the FDR fecal microbiota. Further research is required to investigate the strain level and active functional profiles of FDR and CeD microbiota to better understand the role of gut microbiome in pathophysiology of CeD.

1 March 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SGSimona Gatti
Simona Gatti
ELElena Lionetti
Elena Lionetti
LBLinda Balanzoni
Linda Balanzoni
Anil K. VermaAnil K. Verma
Anil K. Verma
TGTiziana Galeazzi
Tiziana Galeazzi
ACAnna Maria Colombari
Anna Maria Colombari

7 February 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
Anil K. VermaAnil K. Verma
Anil K. Verma
SGSimona Gatti
Simona Gatti
TGtiziana galeazzi
tiziana galeazzi
CMChiara Monachesi
Chiara Monachesi
LPLucia Padella
Lucia Padella
Carlo CatassiCarlo Catassi
Carlo Catassi
Background: A strict and lifelong gluten-free diet is the only treatment of celiac disease. Gluten contamination has been frequently reported in nominally gluten-free products. The aim of this study was to test the level of gluten contamination in gluten-free products currently available in the Italian market. Method: A total of 200 commercially available gluten-free products (including both naturally and certified gluten-free products) were randomly collected from different Italian supermarkets. The gluten content was determined by the R5 ELISA Kit approved by EU regulations. Results: Gluten level was lower than 10 part per million (ppm) in 173 products (86.5%), between 10 and 20 ppm in 9 (4.5%), and higher than 20 ppm in 18 (9%), respectively. In contaminated foodstuff (gluten > 20 ppm) the amount of gluten was almost exclusively in the range of a very low gluten content. Contaminated products most commonly belonged to oats-, buckwheat-, and lentils-based items. Certified and higher cost gluten-free products were less commonly contaminated by gluten. Conclusion: Gluten contamination in either naturally or labeled gluten-free products marketed in Italy is nowadays uncommon and usually mild on a quantitative basis. A program of systematic sampling of gluten-free food is needed to promptly disclose at-risk products.